바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev
e-Submission

Vol.68 No.1
Citation Share

A Case of Fatal Hyperinfective Strongyloidiasis with Acute Respiratory Failure and Intestinal Perforation in Lung Cancer Patient

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.68 no.1, pp.29-33











& (2010). A Case of Fatal Hyperinfective Strongyloidiasis with Acute Respiratory Failure and Intestinal Perforation in Lung Cancer Patient. Tuberculosis & Respiratory Diseases, 68(1), 29-33.
  • Downloaded
  • Viewed
PDF Download

Abstract

Strongyloides stercoralis is an intestinal nematode that is a parasite to humans. The infecting filariform larvae of S. stercoralis enters the host body via the bloodstream, passes through the lungs, penetrates the alveoli, and then ascends the airway to transit down the esophagus into the small bowel. The infection can persist for decades without causing major symptoms and can elicit eosinophilia of varying magnitudes. Of note, this infection can also develop into a disseminated, often fatal, disease (hyperinfection) in patients receiving immunosuppressive corticosteroids. A 65-year-old man who was receiving corticosteroid therapy for the treatment of spinal stenosis was admitted to the emergency room with complaints of abdominal pain and severe dyspnea. We detected many S. stercoralis larvae in the sputum and in the bronchoalveolar-lavage sample collected by bronchoscopy. Here, we report a fatal case of strongyloidiasis with acute respiratory failure and intestinal perforation. In addition, we provide a brief review of the relevant medical literature.

keywords
Strongyloides stercoralis, Respiratory Insufficiency, Intestinal Perforation, Immunosuppression

Reference

1.

1. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 2007;41:1992-2001.

2.

2. Pearlman E. Pathogenesis and immunity in helminthic infection. In: Mahmoud AA, editor. Parasitic lung diseases.New York: Marcel Dekker; 1997. p. 33-46.

3.

3. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004;17:208-17.

4.

4. Weller PF. Eosinophilia and eosinophil-related disorders.In: Adkinson NF Jr, Busse WW, Bochner BS, Holgate ST, Simons FE, Lemanske RF Jr, editors. Middleton’s allergy: principles & practice. 7th ed. Philadelphia:Mosby; 2009. p. 859-77.

5.

5. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001;33:1040-7.

6.

6. Wehner JH, Kirsch CM. Pulmonary manifestations of strongyloidiasis. Semin Respir Infect 1997;12:122-9.

7.

7. Mahmoud AA. Strongyloidiasis. Clin Infect Dis 1996;23:949-52.

8.

8. Fishman JA. Helminthic diseases of the lungs. In:Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Fishman's pulmonary diseases and disorders. 4th ed. New York: McGraw-Hill; 2008.p. 2413- 26.

9.

9. Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF. Strongyloides hyperinfection presenting as acute respiratory failure and gram negative sepsis. Chest 2005;128:3681-4.

10.

10. Feldman M, Friedman LS, Sleisenger MH. Sleisenger & Fordtran’s gastrointestinal and liver disease. 7th ed.Philadelphia: W.B. Saunders; 2002. p. 1954-5.

11.

11. Wilson ME, Weller PF. Eosinophilia. In: Guerrant RL,Walker DH, Weller PF, editors. Tropical infectious diseases:principles, pathogenesis, and practice. 2nd ed.Philadelphia: Churchill Livingstone; 2006. p. 1478-95.

12.

12. Savage D, Foadi M, Haworth C, Grant A. Marked eosinophilia in an immunosuppressed patient with strongyloidiasis.J Intern Med 1994;236:473-5.

13.

13. Gill GV, Bailey JW. Eosinophilia as a marker for chronic strongyloidiasis: use of a serum ELISA test to detect asymptomatic cases. Ann Trop Med Parasitol 1989;83:249-52.

14.

14. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sánchez-Sánchez P, Matogo-Oyana J, Rodríguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004;5:2615-9.

15.

15. Satoh M, Kokaze A. Treatment strategies in controlling strongyloidiasis. Expert Opin Pharmacother 2004;5:2293-301.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy